Fuzuopali New

Data Sheet For research use only. Not for human use.

Cat. No. ：BCP38585CAS No. ：1358715-18-0Purity：98%

Get Quotation Now

Tel: 0086-13026320035 or orders@biochempartner.com

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

Product name			* Applicant name
Catalog Number			* Institution/Company
* Email address			Phone number
Country			* Quantity Required
Remarks

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name			* Applicant name
Catalog Number			* Institution/Company
* Email address			Phone number
Country			* Quantity Required
Remarks

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name			* Applicant name
Catalog Number			* Institution/Company
* Email address			Phone number
Country			* Quantity Required
Remarks

Chemical Properties&Biological Activity

CAS No.	1358715-18-0	Cat. No.	BCP38585
Name	Fuzuopali
Synonyms	SHR-3162;SHR 3162;SHR3162;
SMILES	C1CN2C(=NC(=N2)C(F)(F)F)CN1C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
Chemical Name
Formula	C22H16F4N6O2	M. Wt	472.4
Purity	98%	Storage	Store at 4-8°C
Description	Fluzoparib is a selective poly [ADP-ribose] polymerase 1 (PARP1) and poly [ADP-ribose] polymerase 2 inhibitor (PARP2), being developed by Jiangsu HengRui Medicine, for the treatment of cancer. PARP enzymes play a vital role in repair of DNA damage and maintaining genomic stability. Fluzoparib inhibits PARP enzymes and induces DNA-double strands breaks, G2/M arrest and apoptosis in homologous recombination repair (HR)-deficient cells. Clinical development for ovarian cancer, breast cancer, fallopian tube cancer, peritoneal cancer, gastric cancer and solid tumours is underway in China and Australia. An orally available inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2, with potential antineoplastic activity. Upon oral administration, fluzoparib inhibits PARP 1 and 2 activity, which inhibits PARP-mediated repair of damaged DNA via the base excision repair (BER) pathway, enhances the accumulation of DNA strand breaks, promotes genomic instability, and leads to an induction of apoptosis. The PARP family of proteins catalyze post-translational ADP-ribosylation of nuclear proteins, which then transduce signals to recruit other proteins to repair damaged DNA. PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance.